To the full analysis
Buyback calculator for Beam Therapeutics
Beam Therapeutics stock: key metrics
BEAMBeam Therapeutics had an operating margin of −274.6% and a return on invested capital (ROIC) of −26.1% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2017 | no data | no data | no data |
| 2018 | no data | no data | no data |
| 2019 | −303,338.9% | −417,522.2% | −435,144.4% |
| 2020 | −429,812.5% | −553,166.7% | −810,800.0% |
| 2021 | −347.8% | −757.0% | −714.9% |
| 2022 | −411.5% | −555.6% | −474.5% |
| 2023 | 100.0% | −46.7% | −35.1% |
| 2024 | −478.7% | −654.3% | −593.1% |
| 2025 | 84.0% | −274.6% | −57.2% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2017 | 200.0% | no data | −100.0% |
| 2018 | −86.0% | −52.3% | −69.0% |
| 2019 | −77.6% | −44.0% | −50.2% |
| 2020 | −79.2% | −43.7% | −43.1% |
| 2021 | −44.8% | −38.4% | −25.1% |
| 2022 | −39.4% | −22.5% | −21.5% |
| 2023 | −13.5% | −11.8% | −9.1% |
| 2024 | −51.4% | −30.2% | −34.1% |
| 2025 | −6.5% | −26.1% | −5.4% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 26 Jun 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.